These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16403018)

  • 1. Recognition of DNA modified by trans-[PtClNH(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex.
    Stehlíková K; Kaspárková J; Nováková O; Martínez A; Moreno V; Brabec V
    FEBS J; 2006 Jan; 273(2):301-14. PubMed ID: 16403018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA binding by antitumor trans-[PtCl2(NH3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts.
    Kasparkova J; Novakova O; Farrell N; Brabec V
    Biochemistry; 2003 Jan; 42(3):792-800. PubMed ID: 12534292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of the geometry of the central coordination sphere in antitumor trinuclear platinum complexes on DNA binding.
    Kasparkova J; Vrana O; Farrell N; Brabec V
    J Inorg Biochem; 2004 Oct; 98(10):1560-9. PubMed ID: 15458817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA interactions of new antitumor platinum complexes with trans geometry activated by a 2-metylbutylamine or sec-butylamine ligand.
    Prokop R; Kasparkova J; Novakova O; Marini V; Pizarro AM; Navarro-Ranninger C; Brabec V
    Biochem Pharmacol; 2004 Mar; 67(6):1097-109. PubMed ID: 15006546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biophysical analysis of natural, double-helical DNA modified by a dinuclear platinum(II) organometallic compound in a cell-free medium.
    Marini V; Kasparkova J; Novakova O; Monsú Scolaro L; Romeo R; Brabec V
    J Biol Inorg Chem; 2002 Sep; 7(7-8):725-34. PubMed ID: 12203009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA interactions of new cytotoxic tetrafunctional dinuclear platinum complex trans,trans-[{PtCl2(NH3)}2(piperazine)].
    Brabec V; Christofis P; Slámová M; Kostrhunová H; Nováková O; Najajreh Y; Gibson D; Kaspárková J
    Biochem Pharmacol; 2007 Jun; 73(12):1887-900. PubMed ID: 17400194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis, characterization and biological activity of trans-platinum(II) and trans-platinum(IV) complexes with 4-hydroxymethylpyridine.
    Martínez A; Lorenzo J; Prieto MJ; de Llorens R; Font-Bardia M; Solans X; Avilés FX; Moreno V
    Chembiochem; 2005 Nov; 6(11):2068-77. PubMed ID: 16222727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of p53 in the cellular toxicity by active trans-platinum complexes containing isopropylamine and hydroxymethylpyridine.
    Ramos-Lima FJ; Moneo V; Quiroga AG; Carnero A; Navarro-Ranninger C
    Eur J Med Chem; 2010 Jan; 45(1):134-41. PubMed ID: 19853978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of trans geometry in bifunctional mononuclear platinum complexes by a non-bulky methylamine ligand.
    Frybortova M; Novakova O; Stepankova J; Novohradsky V; Gibson D; Kasparkova J; Brabec V
    J Inorg Biochem; 2013 Sep; 126():46-54. PubMed ID: 23770803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA interactions of antitumor trans-[PtCl2(NH3)(quinoline)].
    Zákovská A; Nováková O; Balcarová Z; Bierbach U; Farrell N; Brabec V
    Eur J Biochem; 1998 Jun; 254(3):547-57. PubMed ID: 9688265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural characterization, DNA interactions, and cytotoxicity of new transplatin analogues containing one aliphatic and one planar heterocyclic amine ligand.
    Ramos-Lima FJ; Vrána O; Quiroga AG; Navarro-Ranninger C; Halámiková A; Rybnícková H; Hejmalová L; Brabec V
    J Med Chem; 2006 Apr; 49(8):2640-51. PubMed ID: 16610807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J; Novakova O; Najajreh Y; Gibson D; Perez JM; Brabec V
    Chem Res Toxicol; 2003 Nov; 16(11):1424-32. PubMed ID: 14615968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the position of substituents in the cytotoxic activity of trans platinum complexes with hydroxymethyl pyridines.
    Martínez A; Lorenzo J; Prieto MJ; Font-Bardia M; Solans X; Avilés FX; Moreno V
    Bioorg Med Chem; 2007 Jan; 15(2):969-79. PubMed ID: 17088064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexes.
    Novakova O; Kasparkova J; Malina J; Natile G; Brabec V
    Nucleic Acids Res; 2003 Nov; 31(22):6450-60. PubMed ID: 14602903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different recognition of DNA modified by aatitumor cisplatin and its clinically ineffective trans isomer by tumor suppressor protein p53.
    Kasparkova J; Pospisilova S; Brabec V
    J Biol Chem; 2001 May; 276(19):16064-9. PubMed ID: 11279186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity, mutagenicity, cellular uptake, DNA and glutathione interactions of lipophilic trans-platinum complexes tethered to 1-adamantylamine.
    Halámiková A; Heringová P; Kaspárková J; Intini FP; Natile G; Nemirovski A; Gibson D; Brabec V
    J Inorg Biochem; 2008; 102(5-6):1077-89. PubMed ID: 18237783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DNA interactions of a novel platinum drug, cis-[PtCl(NH3)2(N7-acyclovir)]+.
    Balcarová Z; Kaspárková J; Zákovská A; Nováková O; Sivo MF; Natile G; Brabec V
    Mol Pharmacol; 1998 May; 53(5):846-55. PubMed ID: 9584210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytotoxicity and DNA binding mode of new platinum-iminoether derivatives with different configuration at the iminoether ligands.
    Boccarelli A; Coluccia M; Intini FP; Natile G; Locker D; Leng M
    Anticancer Drug Des; 1999 Jun; 14(3):253-64. PubMed ID: 10500500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of antitumor trans-[PtCl2(E-iminoether)2] on B-->Z transition in DNA.
    Zaludová R; Natile G; Brabec V
    Anticancer Drug Des; 1997 Jun; 12(4):295-309. PubMed ID: 9199661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.